Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study-Reference-Cited by-同舟云学术

Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study

Published:2012-09-19 Issue:11 Volume:84 Page:1710-1718
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Morand-Joubert Laurence,Ghosn Jade,Delaugerre Constance,Giffo Boniface,Solas Caroline,Samri Assia,Pinta Alexandrina,Triglia Aurore,Raffi François,

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jmv.23388/fullpdf

Reference37 articles.

1. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication;Alatrakchi;AIDS,2005

2. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01);Avettand-Fenoel;J Med Virol,2009

3. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects;Buzon;Nat Med,2010

4. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials;Clotet;Lancet,2007

5. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: The INTENSE study;Clotet;J Antimicrob Chemother,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review;Antiviral Therapy;2023-05-22

2. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus;Value in Health;2022-12

3. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States;JAIDS Journal of Acquired Immune Deficiency Syndromes;2020-02-01

4. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression;Journal of Antimicrobial Chemotherapy;2015-12-16

5. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen;Journal of Antimicrobial Chemotherapy;2014-05-09